Jia Li, Patwari Yasmeen, Kelsey Stephen M, Srinivasula Srinivasa M, Agrawal Samir G, Alnemri Emad S, Newland Adrian C
Department of Haematology/Oncology, St Bartholomew's, The Royal School of Medicine and Dentistry, London El 2AD, UK.
Oncogene. 2003 Mar 20;22(11):1589-99. doi: 10.1038/sj.onc.1206322.
Smac (or DIABLO) is a recently identified, novel proapoptotic molecule, which is released from mitochondria into the cytosol during apoptosis. Smac functions by eliminating the caspase-inhibitory properties of the inhibitors of apoptosis proteins (IAP), particularly XIAP. In this study, we stably transfected both full-length (FL) and mature (MT) Smac genes into the K562 and CEM leukaemic cell lines. Both FL and MT Smac transfectants increased the sensitivity of leukaemic cells to UV light-induced apoptosis and the activation of caspase-9 and caspase-3. Purified cytosol from the mature Smac transfectants, or the addition of human recombinant Smac protein or N-7 peptide into nontransfected cytosol, showed an increased sensitivity to cytochrome c-induced activation of caspase-3. The mature Smac enhanced the susceptibility of both K562 and CEM cells to TRAIL-induced apoptosis. Overexpression of the mature Smac protein also inhibited proliferation, as detected by reduced colony formation and Ki-67 expression in leukaemic cells. Cell cycle analysis revealed that Smac transfectants displayed significant G0/G1 arrest and reduction in 5-bromo-2'-deoxyuridine (BrdU) incorporation. Smac sensitized human acute myeloid leukaemia blasts to cytochrome c-induced activation of caspase-3. However, Smac failed to overcome Apaf-1-deficiency-mediated resistance to cytochrome c in primary leukaemic blasts. In summary, this study reveals that Smac/DIABLO exhibits a potential role in increasing apoptosis and suppressing proliferation in human leukaemic cells. Importantly, it also indicates that it is crucial to evaluate the levels of Apaf-1 and XIAP proteins in patient samples before using Smac peptide therapy in the treatment of human leukaemia.
Smac(或DIABLO)是一种最近发现的新型促凋亡分子,在细胞凋亡过程中从线粒体释放到细胞质中。Smac通过消除凋亡抑制蛋白(IAP),特别是XIAP的半胱天冬酶抑制特性来发挥作用。在本研究中,我们将全长(FL)和成熟(MT)Smac基因稳定转染到K562和CEM白血病细胞系中。FL和MT Smac转染子均增加了白血病细胞对紫外线诱导凋亡的敏感性以及半胱天冬酶-9和半胱天冬酶-3的激活。从成熟Smac转染子中纯化的细胞质,或将人重组Smac蛋白或N-7肽添加到未转染的细胞质中,显示出对细胞色素c诱导的半胱天冬酶-3激活的敏感性增加。成熟的Smac增强了K562和CEM细胞对TRAIL诱导凋亡的敏感性。成熟Smac蛋白的过表达也抑制了增殖,这通过白血病细胞中集落形成减少和Ki-67表达降低得以检测。细胞周期分析显示,Smac转染子表现出显著的G0/G1期阻滞和5-溴-2'-脱氧尿苷(BrdU)掺入减少。Smac使人类急性髓系白血病原始细胞对细胞色素c诱导的半胱天冬酶-3激活敏感。然而,Smac未能克服原发性白血病原始细胞中Apaf-1缺陷介导的对细胞色素c的抗性。总之,本研究表明Smac/DIABLO在增加人类白血病细胞凋亡和抑制增殖方面具有潜在作用。重要的是,这也表明在使用Smac肽疗法治疗人类白血病之前,评估患者样本中Apaf-1和XIAP蛋白的水平至关重要。